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ABSTRACT
To date, a plenty of techniques for the detection of JAK2V617F is used over different 
laboratories, with substantial differences in specificity and sensitivity. Therefore, to provide 
reliable and comparable results, the standardization of molecular techniques is mandatory.
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INTRODUCTION
The JAK2V617F mutation represents a hallmark of 
Philadelphia (Ph)- negative myeloproliferative neoplasms 
(MPNs), fulfilling a 2008 World Health Organization 
(WHO) major criterion for the diagnosis of MPNs [1–2]. 
The JAK2V617F mutation is an acquired, somatic mutation 
carried by almost all patients (approximately 95%) with 
polycythemia vera (PV) and in more than half (approximately 
50–60%) of those with essential thrombocythemia (ET) or 
primary myelofibrosis (PMF) [3, 4].
The assessment of the JAK2V617F allele burden (AB) 
is a common practice either at diagnosis, for prognostic 
information, or during treatment as a means to assess 
minimal residual disease [5]. Indeed, JAK2V617F AB seems 
to be correlated with an increased risk of thrombosis and 
evolution in a secondary myelofibrosis in PV (PPV-MF) 
and, possibly, in ET (PET-MF) [6,7]. Additionally, low 
AB is associated with a reduced survival in PMF [8–11]. 
With regard to drug therapy, several studies showed that 
interferon-alpha, and the most recent telomerase inhibitors 
(Imetelstat), significantly reduces JAK2V617F mutation 
burden, whereas, JAK inhibitors and hydroxyhurea (HU) 
did not have any significant effects [12–21]. Moreover, 
JAK2V617F quantification has been incorporated as a 
potentially useful tool to predict relapse in those patients 
who underwent allogeneic stem-cell transplantation 
(alloHSCT). In this setting of patients, early monitoring 
of the AB (1, 3 and 6 months post alloHSCT) is crucial 
to predict overall survival and risk of relapse and might 
guide therapeutic decisions [22–24].
To date, a plenty of techniques for JAK2V617F 
determination is used over different laboratories, with 
substantial differences in specificity and sensitivity 
[5, 25–31]. The extensive and worldwide use of molecular 
techniques with high sensitivity has significantly increased 
our ability to detect small mutated clones, with low AB 
(i.e. <1% of mutation loads) [5, 26, 32]. Additionally, many 
recent studies have shown that a small clonal hematopoiesis 
may be present also in otherwise healthy subjects at low 
level (0.03–1%) [27, 32–38]. In the context of highly 
sensitive allele-specific assays and low mutant AB in the 
peripheral blood, the possibility of both false-positive and 
false-negative test results is not negligible [5, 32].
Therefore, to provide a reliable and comparable 
molecular results, the standardization of molecular 
techniques is urgently needed. In a recent study by 
European LeukemiaNet/MPN&MPNr-EuroNet group, 
nine different JAK2V617F quantitative assays were evaluated 
by the 12 participant laboratories, with the aim to identify 
the most robust one for routine diagnostic purpose and also 
for post alloHSCT monitoring [39]. Therefore, a network 
of 19 Italian laboratories was established with the aim 1) 
to evaluate the inter- and intra-laboratory variability in 
JAK2V617F quantification in these 19 centers, 2) to identify 
the most robust assay for the standardization of the 
molecular test and 3) to allow consistent interpretation of 
individual patient analysis results.
RESULTS
Between 2014 and 2015, a network of 19 Italian 
laboratories, routinely involved in the molecular diagnosis 
of MPNs, was established. The study was coordinated 
by the Institute of Hematology “L. e A. Seràgnoli”, 
Bologna, and conceived in 3 different rounds in which 
seven, ten and nineteen laboratories were included over 
time, respectively (Figure 1). Overall, one quantitative 
(ipsogen JAK2 MutaQuant kit, QIAGEN) and four 
qualitative assays were evaluated. Of these latter, two were 
commercial (ipsogen JAK2 MutaSearch kit, QIAGEN, and 
GeneQuality JAK-2, AB Analitica) and two were built 
A network of 19 centers was established to 1) evaluate the inter- and intra-
laboratory variability in JAK2V617F quantification, 2) identify the most robust assay for the 
standardization of the molecular test and 3) allow consistent interpretation of individual 
patient analysis results. The study was conceived in 3 different rounds, in which all centers 
had to blindly test DNA samples with different JAK2V617F allele burden (AB) using both 
quantitative and qualitative assays.
The positivity of samples with an AB < 1% was not detected by qualitative assays. 
Conversely, laboratories performing the quantitative approach were able to determine the 
expected JAK2V617F AB. Quantitative results were reliable across all mutation loads with 
moderate variability at low AB (0.1 and 1%; CV = 0.46 and 0.77, respectively). Remarkably, 
all laboratories clearly distinguished between the 0.1 and 1% mutated samples.
In conclusion, a qualitative approach is not sensitive enough to detect the JAK2V617F 
mutation, especially at low AB. On the contrary, the ipsogen JAK2 MutaQuant CE-IVD kit 
resulted in a high, efficient and sensitive quantification detection of all mutation loads. 
This study sets the basis for the standardization of molecular techniques for JAK2V617F 
determination, which will require the employment of approved operating procedures and 
the use of certificated standards, such as the recent WHO 1st International Reference 
Panel for Genomic JAK2V617F.
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“in-house” methods: allele specific polymerase chain 
reaction (AS-PCR) and Amplification-refractory mutation 
system (ARMS) analysis [25, 30].
I Round: proficiency test
In order to obtain information about the variability 
in JAK2V617F quantification between different centers, 
seven laboratories were employed to evaluate several 
DNA samples with their own established JAK2V617F 
qualitative and/or quantitative method. Precisely, four 
DNA samples derived from granulocytes of patients with 
a diagnosis of MPNs  were analyzed. All laboratories 
using the quantitative assay (ipsogen JAK2 MutaQuant 
kit) were able to determine the expected JAK2V617F AB, 
as summarized in Table 1. Only in one case (i.e. DNA 
sample 1), the Center 3 obtained a false positive result. 
Indeed, the sample was found to be positive with an AB of 
0.13%. On the contrary, two Centers (i.e. 6 and 7), using a 
qualitative approach, were not able to detect the positivity 
of the DNA sample 2 (with an expected AB of 0.15%).
II Round: comparison between molecular assays
With the aim to further investigate on the 
inter-laboratory variability in quantifying JAK2V617F 
mutation, especially at low mutation burden, a second 
standardization round was developed and three additional 
laboratories were included. Eight DNA samples, derived 
from dilution of cell lines negative and positive for the 
JAK2V617F mutation, were tested by each laboratory with 
both ipsogen JAK2 MutaQuant kit and their own routine 
qualitative or quantitative method.
We first examined the methods sensitivity, and the 
detection ability of the ipsogen JAK2 MutaQuant kit at 
low-positive samples (i.e. 0.1 and 1%) was compared to 
those of qualitative JAK2 commercial and validated “in-
house” methods. Overall, the ARMS-PCR “in-house” 
method and the ipsogen JAK2 MutaSearch kit were able 
to detect the positivity of the sample with AB of 1%, 
whereas none of the laboratories using any qualitative 
methods were able to detect the low-positive sample 
(i.e. AB < 0.1%). Remarkably, laboratories using the 
quantitative approach clearly defined the positivity of 
both 1% and 0.1% mutated samples. Specifically, 10 
out of 16 JAK2V617F determinations were clearly defined 
positive, with an AB ≥ 0.091% which is the Limit Of 
Detection (LOD) of the ipsogen JAK2 MutaQuant 
kit. In the remaining 6 cases, the JAK2V617F mutation 
percentage was found between Limit of Blank (LOB = 
0.014%) and LOD. 
Additionally, the inter-laboratory variability 
evaluation was restricted to the ipsogen JAK2 
MutaQuant kit, as six out of 10 participating laboratories 
already used this assay in their routine practice. The 
data from two laboratories (i.e. Centers 3 and 8) were 
excluded from statistical analysis, as Negative Controls 
of JAK2V617F mutation (NC-VF) were found to be 
positive (> 0.1%) for each run, and considered as invalid 
runs. This was mainly due to either operator error or to 
instrumentation suitability, instead of an intrinsic bias 
of the kit. Overall, quantitative results between the 
laboratories were reliable as summarized in Table 2 and 
showed in Figure 2. A small variability was observed 
especially at low AB (0.1 and 1%, CV = 0.42 and 0.24, 
respectively).
Figure 1: Design of the study. A network of 19 Italian Centers was established and the study was conceived in 3 different rounds, 
in which seven, ten and nineteen laboratories participated, respectively. Each laboratory had to blindly test DNA samples with different 
JAK2V617F allele burden (AB). Overall, one quantitative and four qualitative assays were evaluated.
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Table 1: I Round JAK2V617F mutation burden and summary statistics (minimum, maximum, 
calculation of median, coefficient of variation) of results obtained by the seven participating 











DNA 1 0.005 0.0056 0.00013 0.13 0 0.0007 0 0.00315 0.13 2.1 Neg Neg
DNA 2 0.15 0.18 0.13 0.19 0.15 0.15 0.13 0.15 0.19 0.15 Neg Neg
DNA 3 5 7.84 4.19 6.2 8.22 6.25 4.19 6.225 8.22 0.24 Pos Pos
DNA 4 20 23.17 25.95 20.24 19.44 19.82 19.44 20.03 25.95 0.08 Pos Pos
The expected JAK2V617F allele burden (AB, %) was 0.005 (DNA 1), 0.15 (DNA 2), 5 (DNA 3) and 20 (DNA 4). Centers 1–5 
performed quantitative assay (ipsogen JAK2 MutaQuant kit) whereas Centers 6 and 7 used a qualitative approach: allele 
specific polymerase chain reaction (AS-PCR) and ipsogen JAK2 MutaSearch kit, respectively.
Table 2: II Round JAK2V617F mutation burden and summary statistics (minimum, maximum, 
calculation of median, coefficient of variation) of results obtained by the ten participating 
laboratories with ipsogen JAK2 MutaQuant kit
Sample Expected JAK2V617F AB (%) Min. Median Max CV (Coefficient of Variation)
DNA G 0 0.002 0.008234 0.02 0.73
DNA E 0.1 0.03 0.09874 0.17 0.42
DNA C 1 0.39 0.8471 1.12 0.24
DNA B 5 2.38 3.643 4.66 0.18
DNA F 10 6.04 8.794 17.65 0.38
DNA H 20 13.12 15.2 19.35 0.11
DNA D 50 30.54 42.62 46.76 0.12
DNA A 100 99.76 99.92 99.97 0.0005
The expected JAK2V617F mutation burden of the eight DNA samples was 0, 0.1, 1, 10, 20, 50 and 100%.
Figure 2: II Round. ipsogen JAK2 MutaQuant kit Copy number (CN) boxplot of JAK2 wild-type (WT), JAK2 mutated (V617F) and 
JAK2 total (A) and JAK2V617F mutation percentage boxplot (B) for each of the 8 DNA samples. Red dots are expected values.
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III Round: inter-laboratory standardization by 
ipsogen JAK2 MutaQuant kit
The study was extended to 9 additional centers to 
confirm the robustness of the ipsogen JAK2 MutaQuant kit 
in a larger cohort. Each participating laboratory had to test 
four DNA samples, derived from dilution of cell lines as 
described above, only with ipsogen JAK2 MutaQuant kit. 
The quantification data from Center 11 were 
excluded from statistical analysis, as NC-VF was 
found to be positive (> 0.1%) for each run and Positive 
Control of JAK2V617F mutation (PC-VF) did not reach the 
recommended value (> 99.9%). Moreover Center 9 failed 
to perform correctly both runs due to instrument failure. 
Of note, both Center 9 and Center 11 did not assess 
JAK2V617F AB in their own routine practice.  Among the 
remaining laboratories, Centers 2, 6 and 17 did not reach 
the minimum number of JAK2 total copy number required 
(10.000 copies) in five different determinations (two at 
0.1% AB sample, two at 1% and one at 10%, respectively), 
and, therefore,  these points were not included in the 
analysis. Quantitative results were reliable across all 
mutation loads, as reported in Table 3 and showed in 
Figure 3. All the 17 laboratories were able to quantify the 
0.1% AB sample with the same  variability observed in 
the previous II round (CV = 0.46 and 0.42, respectively). 
Specifically, 23 out of 32 JAK2V617F determinations were 
clearly defined positive, with an AB > 0.091% (LOD). In 
the remaining 9 cases, the JAK2V617F mutation percentage 
was found between LOB and LOD. Surprisingly, a higher 
variability between laboratories was observed at 1% of AB 
(CV = 0.77, vs 0.24 in the II round). More importantly, all 
laboratories clearly distinguished between the 0.1 and 1% 
mutated samples. 
We also evaluated  the robustness of the quantitative 
approach in terms of amplification efficiency. It is well 
known that amplification efficiency in PCR measures 
the amount of template converted into amplified product 
during each cycle of the exponential phase of the reaction. 
At 100% efficiency, the quantity of product exactly doubles 
each cycle, thus an efficiency close to 100% is the best 
indicator of a robust, reproducible assay. An amplification 
efficiency of 90–105% is recommended for each assay. 
In our study, the mean value of amplification efficiency 
obtained, with respect to all runs performed, was of 92% 
with a CV value of 0.065, confirming the sensitivity and 
the robustness of the ipsogen JAK2 MutaQuant kit. 
DISCUSSION AND CONCLUSIONS
In this study we demonstrated that a qualitative 
approach is not sensitive enough to detect JAK2V617F 
mutation at low mutation burden (i.e. < 1%). Conversely, 
the quantitative approach proved to be highly efficient 
and sensitive, although a modest variability was observed 
between all participating centers, both in the II and in the 
III round (CV = 0.42 and 0.46, respectively). Interestingly, 
only the qualitative ARMS-PCR methods (both “in-house” 
and ipsogen JAK2 MutaSearch kit) and the quantitative 
approach were able to detect the  positivity of samples 
with and AB of 1%. An acceptable variability was 
observed at this AB in the II round (CV = 0.24) whereas 
a higher inter-laboratory variability was registered in the 
III one (CV = 0.77). With regard to samples with AB > 
1%, a lower inter-laboratory variability was observed, as 
demonstrated by CV which ranges from a minimum of 
0.0005 to a maximum of 0.38.
Overall, the quantitative ipsogen JAK2 MutaQuant 
kit assay performed consistently across different platforms, 
affirming itself as a robust method to obtain comparable 
results. This is confirmed by optimal amplification 
efficiency obtained from each laboratory involved in the 
study. Indeed, the mean efficiency obtained in  this study 
was of 92%  with a CV of 0.065. The observed variability 
can be explained with both differences in laboratory 
experience in JAK2V617F quantitative determination and 
intrinsic instrumental bias, as happened in our study, 
with some laboratories experiencing technical issues. 
This, together with the variability observed at low AB 
samples, highlights the need for the standardization of 
practices, including both pre-analytical and analytical 
phases. To this aim, the WHO 1st International Reference 
Panel for Genomic JAK2 V617F (WHO document WHO/
BS/2016.2293) was established in 2016 by the Expert 
Committee on Biological Standardization of the World 
Health Organization [40]. The availability of JAK2V617F 
primary standards should improve the quality of MPN 
genomic diagnostics by enabling the calibration of assays 
and kits, and the derivation of secondary standards for 
routine diagnostic use in determining testing accuracy and 
sensitivity, thus providing inter-laboratory comparison 
towards the harmonization of JAK2V617F testing.
Moreover, we are considering evaluating digital 
PCR (dPCR). This emerging technology may improve 
the ability to detect rare mutations and/or low-positive 
samples due to higher sensitivity and precision, especially 
during follow-up to assess minimal residual disease or 
to monitor patients post alloHSCT [41–42]. But further 
studies are needed on this technology to reach the level of 
standardization of real-time qPCR.
In conclusion, this study sets the basis for the 
standardization of molecular techniques for JAK2V617F 
determination which will require the employment of 
approved operating procedures and the use of certificated 
standards to calibrate JAK2V617F quantitative assays. 
MATERIALS AND METHODS
The study was conceived in 3 different rounds, in 
which 19 Italian laboratories were employed. Centers 9 
and 16 did not perform JAK2V617F molecular testing in their 
routine. Of the remaining centers, 8 used only a quantitative 
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approach (2 “in-house” and 1 commercial assays), 7 
performed only a qualitative evaluation (1 “in-house” 
and 3 commercial assay) of JAK2V617F mutation whereas 2 
laboratories used both qualitative and quantitative 
approaches (2 “in-house” and 1 commercial assays). 
Regarding real-time PCR instruments used during the 
study: most (13 out of 19) of the laboratories used Applied 
Biosystem platforms (ABI7300/7500/7900; Applied 
Biosystem, Foster City, CA, USA); two laboratories used 
a Lightcycler LC480 platform (Roche Applied Science, 
Penzberg, Germany), and the remaining four laboratories 
used a Rotor-Gene Q 2plex/MDx 5plex HRM instrument 
(QIAGEN GmbH, Hilden, Germany) (Table 4). 
I Round
In the I round, we aimed to investigate the inter-
laboratory variability on different mutation loads. In this 
first step, seven laboratories were involved (Center 1–7). 
Four of them routinely performed quantitative analysis of 
JAK2V617F with ipsogen JAK2 MutaQuant Kit (QIAGEN), 
two used a qualitative approach for JAK2V617F evaluation 
(1 “in-house” method, 1 ipsogen JAK2 MutaScreen Kit 
- QIAGEN) whereas one laboratory (Center 5) assessed 
both qualitative and quantitative assays. Each center had 
to test four DNA samples (DNA 1–4) with the method 
routinely employed in their own laboratory. DNA samples 
were isolated from granulocytes of patients with diagnosis 
of MPNs. The expected mutation burden of the 4 DNA 
samples was 0.005 (DNA 1), 0.15 (DNA 2), 5 (DNA 3) 
and 20% (DNA 4), as previously quantified by Bologna’s 
laboratory with ipsogen JAK2 MutaQuant Kit.
All patients provided an informed written consent in 
accordance with the Declaration of Helsinki for the use of 
remnant DNA for investigational purposes. The study was 
approved by the local Ethics Committee. 
II Round
To further investigate the inter-laboratory variability 
on low-positive samples, a II round was developed. The 
two main objectives of this round were to assess inter-
laboratory variability across the 10 participating clinical 
centers and to compare the low-positive sample detection 
ability of the ipsogen JAK2 MutaQuant kit with the JAK2 
validated “in-house” methods. Compared to the first round, 
three additional centers (Centers 8–10) were included 
in this step: only Center 8 and 10 routinely performed 
JAK2V617F evaluation (1 with a qualitative and 1 with a 
quantitative method, respectively). Eight DNA test samples 
(DNA Samples A-H) were manufactured by QIAGEN and 
were centrally distributed by Werfen. The DNA samples 
were derived from dilution of cell lines: K562 (JAK2V617F 
negative) and MUTZ-8 (JAK2V617F positive). The ipsogen 
JAK2 MutaQuant kits and associated master-mix were 
provided by QIAGEN and Werfen. Each center had to 
Table 3: III Round JAK2V617F mutation burden and summary statistics (minimum, maximum, 
calculation of median, coefficient of variation) of results obtained by the nineteen participating 
laboratories with ipsogen JAK2 MutaQuant kit
Sample Expected JAK2V617F AB (%) Min. Median Max CV (Coefficient of Variation)
S02 0.1 0.07 0.11 0.27 0.46
S04 1 0.64 1.05 4.90 0.77
S01 10 6.67 10.04 24.37 0.37
S03 100 99.79 99.92 99.97 0.0005
The expected JAK2V617F mutation burden of the four DNA samples was 0.1, 1, 10 and 100%. 
Figure 3: III Round. ipsogen JAK2 MutaQuant kit Copy number (CN) boxplot of JAK2 wild-type (WT), JAK2 mutated (V617F) and 
JAK2V617F mutation percentage boxplot for each of the 4 DNA samples. Red dots are expected values.
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blindly test the DNA samples in four different runs: 2 runs 
were performed with the ipsogen JAK2 MutaQuant kit 
and 2 runs with their validated qualitative or quantitative 
method. The expected mutation burden of the DNA 
samples was 0, 0.1, 1, 10, 20, 50 and 100%. 
III Round
The III round was intended to confirm the robustness 
of the ipsogen JAK2 MutaQuant kit. Qualitative methods 
were therefore excluded and the study was extended to 9 
additional laboratories (Centers 11–19). Centers 12, 13 and 
17 routinely assessed quantitative evaluation of JAK2V617F 
mutation (2 “in-house” and 1 commercial methods), 4 
laboratories (Centers 11, 15, 18 and 19) used qualitative 
assays (1 “in-house” and 1 commercial methods), Center 
14 performed both qualitative (“in-house”) and quantitative 
(ipsogen JAK2 MutaQuant kit) analysis whereas Center 16 
did not perform JAK2V617F molecular testing in its routine. 
Four DNA test samples (DNA Samples S01-S04), provided 
Table 4: Summary of participating centers, methods used in their routine practice for JAK2V617F 
detection and instrumentation used in their routine and/or in the study (specified when different)
ID Center Method Instrumentation
1 Quantitative ipsogen JAK2 MutaQuant kit Applied Biosystem 7900HT Fast* Real-Time PCR System
2 Quantitative ipsogen JAK2 MutaQuant kit Applied Biosystems 7300 Real-Time PCR System
3 Quantitative ipsogen JAK2 MutaQuant kit
Rotor-Gene Q 2plex HRM System
Rotor-Gene Q MDx 5plex HRM System (3rd 
Round)





ARMS PCR (Chen et al., 2007) [30]
ipsogen JAK2 MutaQuant kit 7500 Real Time PCR System Life Technologies
6 Qualitative home-made
Allele-specific PCR
(Baxter et al, Lancet 2005) [25]
LightCycler 480
(2nd and 3rd Round)
7 Qualitative ipsogen JAK2 MutaSearch Applied Biosystems 7300 Real-Time PCR System
8 Qualitative AB Analitica GeneQuality JAK-2 kit Applied Biosystems 7300 Real-Time PCR System
9 N.A. N.A. LightCycler 480 (2nd and 3rd Round)
10 Quantitative ipsogen JAK2 MutaQuant kit Applied Biosystems 7500 Fast* Real-time PCR System
11 Qualitative home-made
Allele-specific PCR
(Baxter et al, Lancet 2005) [25] Rotor-Gene Q MDx 5plex HRM (3rd Round) 
12 Quantitative ipsogen JAK2 MutaQuant kit Rotor-Gene Q MDx 5plex HRM 
13 Quantitative home-made
Allele-specific primers (0,1-25%) Allele-
specific hydrolysis probes (10–90%)







(Baxter et al, Lancet 2005) [25]
ipsogen JAK2 MutaQuant kit
Applied Biosystems 7500 Real-time PCR System
15 Qualitative ipsogen JAK2 MutaScreen Applied Biosystems 7500 Fast* Dx PCR System
16 N.A. N.A. Applied Biosystems 7500 Fast* Real-time PCR System
17 Quantitative home-made
Allele-specific PCR
(Søren Germer et al, Genome Res. 2000) ABI PRISM 7900 HT SDS
18 Qualitative ipsogen JAK2 MutaScreen Applied Biosystems 7500 Real-time PCR System
19 Qualitative ipsogen JAK2 MutaScreen StepOnePlus Real-Time PCR SystemRotor-Gene Q MDx 5plex HRM (3rd Round)
*Fast mode was not used, as the ipsogen JAK2 MutaQuant kit is not compatible with “Fast” mode.
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from the same batches as II round’s DNA Samples, were 
centrally distributed by Werfen. The ipsogen JAK2 
MutaQuant kits and associated master-mix were provided 
by QIAGEN and Werfen. Each laboratory had to blindly 
test the DNA samples in 2 runs with the ipsogen JAK2 
MutaQuant kit. The expected mutation burden of the four 
DNA samples was 0.1, 1, 10 and 100%.
Moreover, amplification efficiency (E) was 
calculated from the slope of the standard curve using the 
following formula: E = 10–1/slope. Amplification efficiency 
was expressed as a percentage, that is the percent of 
template that was amplified in each cycle. To convert 
E into a percentage we used the following formula: % 
Efficiency = (E – 1) × 100%. 
Data collection and run validity check
Raw data were collected and run validity was 
checked according to manufacturer’s instructions in the 
kit’s handbook.
Statistical method
Statistical analysis was carried out by QIAGEN 
and by Bologna University. Wild type and mutation 
copy numbers together with mutation percentage were 
summarized by mean, median, first and third quartiles, 
standard deviation and coefficient of variation and plotted 
by sample for the ipsogen JAK2 MutaQuant kit.
Inter-laboratory variability: II round
Fisher test was performed by sample to compare 
variance in order to conclude on the acceptability of the 
inter-laboratory variability. 
Inter-laboratory variability: III round
Shapiro-Wilk normality test was performed to check 
for data normality and quantile-quantile normal plots were 
employed for data visual inspection. Kruskall-Wallis test was 
applied and multiple comparison post-hoc test (Wilcoxon 
test) was carried out to identify the significant differences. 
False discovery rate correction was applied to avoid increase 
in type I error (false positive) because of multiple testing 
following the Benjamini and Hochberg procedure.
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